Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ankyra Therapeutics, Inc
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
Sanofi
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
BioNTech SE
OncoNano Medicine, Inc.
Regeneron Pharmaceuticals